Transcription and Gene Targeting

Group Leader: Professor Levon Khachigian



Overview of Research


Cardiovascular disease and cancer remain the most prevalent causes of morbidity and mortality. The pathogenesis of these and a myriad of related diseases is underpinned by molecular and cellular changes in our blood vessels. Professor Levon Khachigian’s research is uncovering key networks of transcriptional control and inducible gene-regulatory circuits that lead to vascular disease. The group is also developing new experimental drugs that have the potential to treat a diverse range of health problems, from cancer and inflammation through to eye and heart disease.

Professor Khachigian’s research program has two major objectives:
  1. To better understand how harmful genes are controlled in vascular cells. This arm investigates signaling and transcriptional mechanisms of pro-inflammatory cytokine-dependent gene expression, post-translational mechanisms that modify protein behavior, proteinase control, the isolation and characterization of new genes induced or repressed by vascular cell injury, and the molecular control of vascular cell migration and proliferation. The group has considerable expertise in animal models of neointima formation, angiogenesis, tumor growth, myocardial ischemia, and inflammation.
  2. To develop new vascular therapeutic agents. The lab is harnessing the outcomes of its fundamental research by pioneering the development of novel “anti-gene-” and “gene-therapeutic” strategies targeting key regulatory genes in a myriad of vascular disorders. This involves strategic collaborations with a range of clinical specialists, academics and drug development consultants. Khachigian has laid the framework for groundbreaking clinical trials translating the lab's discovery science into clinical “smart drug molecular assassin” technology. "First-in-man" trials of catalytic DNA molecules (DNAzymes) targeting key immediate-early genes commenced in Sydney in patients with skin cancer in 2010.

PhD, MSc and Hons projects are available in both these research streams in Khachigian Lab in 2013. If you’re interested, please email , sending your CV.

DNAzymes

DNAzymes targeting c-Jun inhibit bone erosion in the collagen-antibody inducible arthritis (CAIA) model. Arrows denote bone-resorbing osteoclasts.
(Fahmy, R., Waldman, A., Zhang, G., Mitchell, A., Tedla, N., Cai, H., Chesterman, C.N., Geczy, C.R., Perry, M.A., Khachigian, L.M. (2006) Nature Biotech 24, 856-863)


Group Members


Professor Levon KhachigianGroup Leader
Dr Lionel Lourenco-DiasPost-doctoral Fellow (NHMRC-INSERM Fellow)
Dr Jianmei LiPost-doctoral Fellow (UNSW Vice Chancellor’s Fellow)
Dr Hong CaiPost-doctoral Fellow
Dr Kristine MalabananPost-doctoral Fellow
Dr Lucinda McRobbPost-doctoral Fellow
Dr Mei-Chun YehPost-doctoral Fellow
Dr Estella Sanchez-GuerreroPost-doctoral Fellow
Fernando SantiagoPost-doctoral Fellow
Cecilia ChanPhD Student
David (Yue) LiPhD Student
An TruongPhD Student
Anjali NathPhD Student
Grace YeePhD Student
Siwei AnMasters Student
Margaret PatrikakisSenior Research Assistant
Annie Au-YeungResearch Assistant/Lab Co-ordinator
Vicki FreemanPersonal Assistant (part-time)

Key Publications


To view key publications from the Khachigian Lab, click here.

Funding Sources




lab images


Contact


Prof Levon Khachigian

T (02) 9385 2537
E


Related Links

Centre for Vascular Research - UNSW - Faculty of Medicine NSW 2052 Australia | Tel: +61 (2) 9385 2536 Fax: +61 (2) 9385 1797
© Copyright 2005 UNSW Faculty of Medicine | CRICOS Provider Code: 00098G | ABN 57 195 873 179 | Authorised by Director, Centre for Vascular Research
Page Last Updated: 04:43:35 PM, Friday 1 February 2013
CONTACTS | SITEMAP | Print Friendly